FDA report accuses Able Labs of fraudulent testing

The FDA says that Able Laboratories fraudulently altered quality tests to hide its failures from regulators. And an FDA report posted on Able's website says that senior management at Able failed to ensure that its products were safe. Changes to lab tests were done by "cutting and pasting" computer records by supervisors and lab workers in the lead-up to a recall of all its products last May. Able produced about 30 generic drugs up until it halted manufacturing operations. Able President Robert Mauro resigned a week ago.

- read this report from USA Today

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

Vanda Pharmaceuticals received a Complete Response Letter from the FDA taking issue with a small study testing Hetlioz in jet lag disorder.